(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026210 A2

(51) International Patent Classification[7]: C07K 16/28, C12N 15/13, 15/62, 15/79, 5/10, A61K 39/395, A61P 37/00

(21) International Application Number:
PCT/EP2004/010471

(22) International Filing Date:
17 September 2004 (17.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/666,332 18 September 2003 (18.09.2003) US
0414309.5 25 June 2004 (25.06.2004) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOLBINGER, Frank** [DE/DE]; Thuner Ring 4, 79395 Neuenburg (DE). **CARBALLIDO HERRERA, José, M.** [ES/AT]; Bernhard Weissgasse 6/3, A-2380 Perchtoldsdorf (AT). **ASZÓDI, András** [HU/AT]; Bujattigasse 15B/19, A-1140 Vienna (AT). **SALDANHA, José, W.** [GB/GB]; 21 Fillebrook Avenue, Enfield, London EN1 3BD (GB). **HALL, Bruce, M.** [AU/AU]; 14 Vernon Street, Strathfield, NSW 2135 (AU). **GREGORI, Silvia** [IT/IT]; Via Romagna, 19, I-20090 Buccinasco (IT). **RONCAROLO, Maria, Grazia** [IT/IT]; Via Fratelli Cervi, Residenza Andromeda i. 131, I-20090 Segrate (IT). **LOUX, Véronique** [FR/FR]; 24, rue du 19 Novembre, F-68870 Bartenheim (FR). **AVERSA, Gregorio** [IT/CA]; 4525 West Sixth Ave., Vancouver, BC V6R IV4 (CA). **JESCHKE, Margit** [DE/CH]; Grenzacher Str. 10, CH-4058 Basel (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/026210 A2

(54) Title: THERAPEUTIC BINDING MOLECULES

(57) Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-IIe-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-ProTyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe -Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-GIy-ThrSer-IIe-Gln (RASQNIGTSIQ), CDR2' having the amino acid sequence Ser-Ser-Ser-Glu-SerIle-Ser (SSSESIS) and CDR3' having the amino acid sequence Gln-GIn-Ser-Asn-Thr-Trp Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.